Provided by Tiger Trade Technology Pte. Ltd.

InMode Ltd.

16.02
+0.90005.95%
Post-market: 15.99-0.0300-0.19%16:57 EST
Volume:2.80M
Turnover:44.49M
Market Cap:1.01B
PE:7.44
High:16.09
Open:15.92
Low:15.69
Close:15.12
52wk High:19.78
52wk Low:13.14
Shares:63.21M
Float Shares:53.49M
Volume Ratio:2.37
T/O Rate:5.23%
Dividend:- -
Dividend Rate:- -
EPS(TTM):2.15
EPS(LYR):2.29
ROE:21.52%
ROA:7.00%
PB:1.55
PE(LYR):7.01

Loading ...

Steel Partners Targets InMode, Citing Stock Underperformance

Benzinga_recent_news
·
4 hours ago

Unusually active option classes on open January 29th

TIPRANKS
·
Yesterday

Deals of the day-Mergers and acquisitions

Reuters
·
Yesterday

Steel Partners presents $18.00 per share offer to acquire 51% of InMode

TIPRANKS
·
Yesterday

Steel: Proposal for Inmode to Be Fully Funded From Cash on Hand & Borrowing Capacity Under Existing Credit Facility, With No Financing Contingency

THOMSON REUTERS
·
Yesterday

Steel: in Absence of Cooperation by Inmode, May Elect to Proceed With Bringing Binding Proposal Directly to Shareholders

THOMSON REUTERS
·
Yesterday

Steel Partners Holdings L.p.: Beneficially Owns About 1.3% of Outstanding Shares of Inmode Ltd.

THOMSON REUTERS
·
Yesterday

BRIEF-Steel Partners Said To Offer $18 Per Share For 51% Of Inmode - Bloomberg News

Reuters
·
Yesterday

Steel Partners Said to Offer $18 per Share for 51% of Inmode - Bloomberg News

THOMSON REUTERS
·
Yesterday

Analysts Offer Insights on Healthcare Companies: Acumen Pharmaceuticals (ABOS) and InMode (INMD)

TIPRANKS
·
Jan 27

InMode Up Over 13%, on Pace for Largest Percent Increase Since November 2023 -- Data Talk

Dow Jones
·
Jan 27

Analysts Have Conflicting Sentiments on These Healthcare Companies: Sarepta Therapeutics (SRPT) and InMode (INMD)

TIPRANKS
·
Jan 26

InMode in talks to be sold for $1.1B to investment fund, Calcalist reports

TIPRANKS
·
Jan 26

Updated 2025–2026 Revenue Guidance Might Change The Case For Investing In InMode (INMD)

Simply Wall St.
·
Jan 11

Analysts Offer Insights on Healthcare Companies: Phathom Pharmaceuticals (PHAT), InMode (INMD) and Bristol-Myers Squibb (BMY)

TIPRANKS
·
Jan 08

Inmode Ltd: Preliminary Non-Gaap Gross Margin for Full Year of 2025 to Be in Range of 78% to 79%

THOMSON REUTERS
·
Jan 08

Inmode Ltd: Preliminary Revenue for Q4 of 2025 to Be in Range of $103.6 Mln to $103.8 Mln

THOMSON REUTERS
·
Jan 08

InMode Ltd. Published an Update to Their Financial Calendar

Reuters
·
Jan 08

InMode Is Maintained at Hold by Canaccord Genuity

Dow Jones
·
Dec 18, 2025

Analysts Offer Insights on Healthcare Companies: RxSight (RXST) and InMode (INMD)

TIPRANKS
·
Nov 06, 2025